Research programme: anti-pox monoclonal antibodies - Tonix Pharmaceuticals Holding Corp
Alternative Names: TNX-3400Latest Information Update: 31 Mar 2023
Price :
$50 *
At a glance
- Originator Tonix Pharmaceuticals Holding Corp
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants; Virus attachment inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Poxvirus infections